Kalaris Therapeutics, Inc.
KLRS
Positions held
Your positionsKLRS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $59.51M | Enterprise value | -$32.63M | Trailing P/E | — | Forward P/E | -1.51 |
| PEG | — | Price / book | 1.03 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -79.9% | ROA | -31.0% | Debt / equity | 0.02 |
| Current ratio | 10.98 | Free cash flow | -$26.24M | Analyst recommendation | strong_buy | Mean target | $18.71 |
| 52w high | $11.88 | 52w low | $2.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$11.5M | -$10.9M | -$10.0M | -$11.9M | -$11.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.4M | -$11.8M | -$10.8M | -$12.7M | -$12.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$43.4M | -$69.2M | -$14.7M | -$15.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$46.2M | -$51.7M | -$13.5M | -$14.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-31 · Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-11 · Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-20 · Kalaris Therapeutics Names Liisa Bayko CFO
2026-07-20 · Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
2026-07-17 · Top Midday Gainers
2026-07-17 · Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD
2026-07-17 · Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
2026-07-14 · Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
Price (daily)
Full chart · RSI · MACD · patterns